INSIGHT. Looking back at pharmaceutical industry acquisition activity in 2024, a clear trend emerges: immunology and cancer dominated. These areas accounted for 70% of total transaction value, sending a strong signal about the industry’s growth potential. According to Biopharma Dive,
INSIGHT. Healthcare systems worldwide are facing significant challenges. An ageing population, growing healthcare needs, and staff shortages are pressuring healthcare providers to find new, more accessible and cost-effective care models. One solution gaining increasing attention is virtual wards. The concept
Your search ends here. By joining Sciety Venture Partners, you have the opportunity to invest alongside Sciety in the most promising life science companies. Not only do you benefit from our extensive research and expertise, but you also become part of a network of like-minded investors.
Let us make health and life science innovations reach their full potential. Sign up to join Sciety Venture Partners and start receiving invitations to investor events, investment opportunities and news.
Sciety Venture Partners comprises private investors, family offices and venture capital firms. Among the members are professionals with extensive experience in the life science field, for example as researchers, entrepreneurs, or investors. We interviewed some of our members and asked why they choose to invest in and support unlisted companies in life science.
Sweden is Northern Europe’s most dynamic market for life sciences, with a strong focus on innovation and collaboration. It is in the top five among the world’s countries in terms of investment in research and development.
An aging population, increasing incidence of lifestyle diseases, and more demanding health care consumers are increasing demand for drugs, innovative medical technology, and digital solutions.
The biotechnological revolution creates new opportunities to develop customized treatments for each individual disease case. This in turn leads to increased demand for precision diagnostics and technology solutions in areas such as genomics.
Growth companies in the biopharma sector are behind the majority of all new drugs approved by the FDA. Increasing numbers of partnership agreements are also being signed between Big Pharma and smaller companies.
Digital solutions are being implemented at a fast pace. Efforts to streamline healthcare processes, cost savings, and improved health care quality as well as increased demand for on-demand care are drivers behind this trend.
Over the past 100 years, the global average life expectancy has more than doubled and is now 73 years. The child mortality rate in the world has declined by nearly 75% since 1950. Significant medical advances are one of the causes behind this positive development.
We’ve got you covered.
At Sciety, we understand that securing an investment is just the first step in building a successful company. That is why our investment is more than just financial capital – it is a long-term partnership.
Our team of experts, including researchers, clinicians, entrepreneurs, and business professionals, brings a unique combination of skills to the table. We are dedicated to helping you reach your full potential and will be by your side every step of the way. Want to learn more?
Evidence has developed a unique SaaS solution with AI functionality, specifically designed for healthcare. Evidence helps management optimize resource use and improve care quality by consolidating all critical functions into a single system.
PeptiSystems has developed a groundbreaking technology for the large-scale production of precision drugs. The company sells instruments for manufacturing peptides and oligonucleotides used in pharmaceutical manufacturing.
Capitainer develops and sells intelligent solutions for self-sampling blood, plasma, and urine. The products enable easy home sampling with market-leading precision, delivering value across the entire care chain.
PharmNovo is a pharmaceutical company at the clinical stage of developing a unique type of treatment for nerve pain (neuropathic pain), a condition currently lacking effective and safe treatment. The company is currently finalising its clinical phase I study and is advancing its preparations for a phase II study.
Sciety combines efficient processes and advanced tech solutions with deep expertise in life science to identify and support the most promising life science innovations. Learn more about our structured and digitalised approach to investing in a healthier future.
